What’s Next? Five Things To Look Out For In May

Teva And Viatris Follow Sandoz On Q1; Key Cabometyx Trial Set To Begin

This month, Eli Lilly’s Alimta blockbuster will lose patent protection in the US, while Teva – which will also publish its Q1 financial results – will see Bristol Myers Squibb begin its appeal process against a key UK ruling involving the originator’s Eliquis (apixaban) anticoagulant.

What's Next Image
May's schedule includes Q1 results and a key ANDA trial • Source: Informa

What will industry giants Teva and Viatris offer up when they publish their first quarter financial results early in this month?

Teva, which will publish first of the two on 3 May, had indicated earlier this year that 2022 was set...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Generics

More from Products